Recent studies suggest a majority of mergers fail. Two tenured professors identified the potential pitfalls and keys to ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

KGaA (MRK:GR) (OTC: MKGAF) stock from Overweight to Equalweight and reduced its price target from EUR190.00 to EUR160.00. The downgrade reflects a shift in the investment firm's perspective on the ...

Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.

German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

President-elect Trump's return to the White House could bring an uptick in mergers and acquisitions, as markets anticipate tax and regulatory reforms that will boost dealmaking. Royal Palm ...

Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...

Singapore's Paragon REIT said it received a buyout offer from its major shareholder, Cuscaden Peak, and parties valuing the real estate firm at S$2.78 billion ($2.05 billion). Merck KGaA, the German ...

Merck & Co Inc on Thursday reported steady top-line growth, though profit took a hit due to the cost of recent acquis ... Subscribe now to see this Premium News article from Alliance News ...